Home » Healthcare » Middle East Human Insulin Market

Middle East Human Insulin Market

Middle East Human Insulin Market By Device (Pens, Syringes, Others); By Indication (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes); By Insulin (Rapid-acting Insulin, Short-acting Insulin, Intermediate-acting Insulin, Others); By Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Providers) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Summary
Table Of Content

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Middle East Human Insulin Market Size 2023	USD 435.75 Million
Middle East Human Insulin Market, CAGR	1.98%
Middle East Human Insulin Market Size 2032	USD 521.17 Million

Market Overview

Middle East Human Insulin Market size was valued at USD 435.75 million in 2023 and is anticipated to reach USD 521.17 million by 2032, at a CAGR of 1.98% during the forecast period (2023-2032).

The Middle East human insulin market is driven by the rising prevalence of diabetes, increasing awareness about early diagnosis and treatment, and growing investments in healthcare infrastructure. A sedentary lifestyle, poor dietary habits, and an aging population contribute significantly to the region’s expanding diabetic population, thereby fueling demand for effective insulin therapies. Governments across the Middle East are launching public health initiatives and expanding access to essential medications, further supporting market growth. Technological advancements in insulin delivery systems, such as insulin pens and pumps, are enhancing patient convenience and adherence, driving adoption. Additionally, the region is witnessing a gradual shift toward biosimilar insulin due to its cost-effectiveness and growing acceptance among healthcare providers. Collaborations between global pharmaceutical companies and regional distributors are also strengthening market reach and availability. These trends collectively underscore a stable and evolving market landscape for human insulin in the Middle East, with steady growth expected over the forecast period.

The Middle East human insulin market is influenced by varying geographical dynamics, with key markets including Saudi Arabia, the UAE, and Egypt. These countries have some of the highest rates of diabetes in the region, driving demand for insulin therapies. Saudi Arabia, with its advanced healthcare infrastructure and high prevalence of diabetes, represents a major market. The UAE also shows a growing need for insulin products due to its rising diabetic population and healthcare initiatives aimed at managing chronic diseases. Egypt, with its large population, presents significant opportunities for insulin manufacturers, especially given the government’s efforts to improve access to treatment. Key players in the Middle East human insulin market include global pharmaceutical giants such as Novo Nordisk, Eli Lilly, and Biocon, alongside regional companies like Wockhardt and Tonghua Dongbao. These companies play a critical role in ensuring insulin availability and affordability across the region, supporting both public health initiatives and increasing demand for diabetes management.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Insights

The Middle East human insulin market was valued at USD 435.75 million in 2023 and is projected to reach USD 521.17 million by 2032, growing at a CAGR of 1.98% during the forecast period.

The global human insulin market was valued at USD 21,000 million in 2023 and is projected to reach USD 31,208 million by 2032, growing at a CAGR of 4.50% from 2023 to 2032.
Rising diabetes prevalence due to sedentary lifestyles, unhealthy diets, and aging populations is a major market driver.
Increased adoption of insulin delivery technologies like insulin pens and pumps is contributing to market growth.
Growing demand for biosimilars in the region is providing cost-effective insulin alternatives.
The market is witnessing strong competition among global players like Novo Nordisk, Eli Lilly, and Biocon, along with regional manufacturers.
High insulin treatment costs and limited access in rural areas remain significant market restraints.
Saudi Arabia, the UAE, and Egypt lead the market, with governments enhancing healthcare access and focusing on diabetes management initiatives.

Report Scope

This report segments the Middle East Human Insulin Market as follows:

Market Drivers

Rising Prevalence of Diabetes

The growing prevalence of diabetes in the Middle East is one of the most significant drivers of the human insulin market. The region has seen a notable increase in the number of people diagnosed with both Type 1 and Type 2 diabetes. For instance, according to the International Diabetes Federation (IDF), the Middle East and North Africa (MENA) region has one of the highest rates of diabetes globally. Contributing factors include sedentary lifestyles, unhealthy eating habits, and rising obesity rates, particularly in countries like Saudi Arabia, UAE, and Qatar. As the diabetic population increases, the demand for insulin therapies—especially human insulin—is surging to manage blood glucose levels effectively. This trend has resulted in a growing market for both traditional and advanced insulin products.

Advancements in Insulin Delivery Technologies

Advancements in insulin delivery technologies are another key factor driving the Middle East human insulin market. For instance, insulin pumps, continuous glucose monitors (CGMs), and insulin pens are transforming diabetes management by offering greater accuracy, convenience, and comfort. These innovations offer patients greater convenience, precision, and flexibility, enhancing treatment adherence. Insulin pens, in particular, are becoming increasingly popular in the region due to their ease of use and portability. The rise of digital health solutions, such as mobile apps that track insulin dosage and glucose levels, is also contributing to the overall market growth. As these technologies become more widely accessible, the market for human insulin in the Middle East continues to expand, driven by both improved treatment options and better patient compliance.

Government Initiatives and Healthcare Reforms

Government initiatives and healthcare reforms in the Middle East are playing a critical role in driving market growth. Several Middle Eastern countries are investing heavily in improving healthcare infrastructure and increasing access to essential medicines, including insulin. Governments are also implementing public health programs aimed at raising awareness about diabetes prevention and management, further contributing to the rising demand for insulin products. For instance, countries like Saudi Arabia and the UAE have introduced national health plans to address the growing burden of diabetes, focusing on early detection, disease management, and better treatment options. The growing emphasis on universal health coverage and increased healthcare spending in the region is making insulin more accessible to a larger portion of the population, thus driving market expansion.

Emergence of Biosimilar Insulin

The increasing availability and adoption of biosimilar insulin products in the Middle East are significantly influencing market dynamics. Biosimilars, which are biologically similar to brand-name insulin but are generally more affordable, are gaining acceptance among healthcare providers and patients alike. The cost-effectiveness of biosimilars has made them an attractive option for governments and healthcare systems in the Middle East, where cost containment is a major concern. In addition, the World Health Organization (WHO) has endorsed biosimilars as safe and effective alternatives to reference insulins, further driving their acceptance. The expansion of biosimilar insulin offerings from leading pharmaceutical companies is likely to fuel competition in the market and provide more treatment options to diabetic patients, thus contributing to the overall growth of the human insulin market in the region.

Market Trends

Shift Toward Biosimilar Insulin

One of the key trends in the Middle East human insulin market is the growing shift towards biosimilar insulin. As the global market for insulin continues to grow, biosimilars have emerged as a cost-effective alternative to branded insulin products. The approval and increasing availability of biosimilars in the Middle East are driving competition among manufacturers and making insulin therapies more affordable. Many Middle Eastern governments, aiming to curb healthcare costs while providing quality care, are increasingly adopting biosimilars as part of their national health strategies. This trend is likely to expand further as more biosimilar insulin options enter the market, providing patients with a broader range of affordable treatment options.

Increase in Personalized Diabetes Management

Another notable trend is the rise of personalized diabetes management, which is changing the way insulin is prescribed and administered in the region. For instance, continuous glucose monitoring (CGM) systems and insulin pumps are increasingly being used to tailor insulin regimens based on individual patient needs. Personalized treatments involve tailoring insulin regimens based on individual patient needs, such as their lifestyle, genetic factors, and disease progression. As these devices become more widely available and affordable in the Middle East, healthcare providers are increasingly focusing on customized care for diabetic patients. This trend not only improves patient outcomes but also supports adherence to insulin therapy, further boosting market demand.

Focus on Public Health Initiatives and Awareness Campaigns

Increasing public health awareness and initiatives focused on diabetes prevention and management are also shaping the human insulin market in the Middle East. For instance, national campaigns and outreach programs are being implemented to address the rising burden of diabetes in the region. Governments and non-governmental organizations are ramping up efforts to educate the population on the importance of early diabetes detection, healthy living, and the availability of treatment options, including insulin. National campaigns and outreach programs are designed to address the rising burden of diabetes in the region, particularly in countries like Saudi Arabia and the UAE, where the incidence of diabetes is notably high. As awareness increases, more individuals are seeking medical consultations, leading to earlier diagnoses and a greater demand for insulin therapy. This trend is expected to contribute to sustained market growth as more patients are empowered to manage their diabetes effectively.

Growing Adoption of Insulin Delivery Devices

The adoption of advanced insulin delivery devices is another important trend driving the human insulin market in the Middle East. Insulin pens, pumps, and auto-injectors are becoming more widely used across the region due to their ease of use, convenience, and ability to deliver accurate doses. Insulin pens, in particular, have become the preferred choice for many patients due to their portability and simplicity compared to traditional vial and syringe methods. Moreover, insulin pumps, which provide continuous insulin delivery, are gaining popularity among patients who require more intensive and precise insulin management, such as those with Type 1 diabetes. As the region’s healthcare infrastructure improves and access to these devices increases, their use is expected to continue to grow, thereby influencing the demand for human insulin.

Market Challenges Analysis

High Treatment Costs and Affordability Issues

A significant challenge facing the human insulin market in the Middle East is the high cost of insulin therapies. Despite the growing availability of biosimilar options, branded insulin products remain expensive, making them inaccessible for a large portion of the population, particularly in lower-income groups. The cost of insulin, along with related devices such as insulin pumps and continuous glucose monitoring systems, poses a substantial financial burden on patients, particularly in countries where healthcare coverage is limited. While some governments in the region have made efforts to subsidize insulin and make it more affordable, the ongoing financial challenge remains a barrier to widespread access. This affordability issue hampers the adoption of insulin therapies, especially in rural or underserved areas, where healthcare infrastructure is less developed.

Regulatory and Distribution Barriers

Another major challenge is the complex regulatory environment and distribution hurdles in the Middle East. For instance, regulatory complexities and market entry barriers have contributed to slower adoption rates for biosimilar insulin. Additionally, there are inconsistencies in the availability and distribution of insulin, particularly in less developed regions. Distribution channels can be inefficient, and logistical challenges, such as maintaining the cold chain for insulin storage, further complicate access to these critical medications. These barriers create uncertainty for both manufacturers and patients, limiting market growth and making it more difficult to ensure consistent supply and equitable access to insulin therapies. As a result, addressing these regulatory and distribution challenges is crucial for unlocking the full potential of the human insulin market in the Middle East.

Market Opportunities

The Middle East human insulin market presents significant opportunities driven by the rising prevalence of diabetes and the increasing focus on healthcare infrastructure development. As the diabetic population continues to grow, particularly in countries with high obesity rates like Saudi Arabia and the UAE, the demand for insulin is expected to rise steadily. This growth is compounded by a greater emphasis on improving healthcare access, with governments and private sectors investing heavily in modernizing healthcare facilities and expanding insurance coverage. These initiatives present a unique opportunity for insulin manufacturers to capitalize on an expanding patient base, particularly by introducing cost-effective biosimilars and advanced insulin delivery systems that can cater to both established and emerging markets in the region.

Additionally, the increasing adoption of digital health technologies and personalized diabetes management presents a compelling opportunity for innovation in the insulin market. The growing use of continuous glucose monitoring (CGM) devices and insulin pumps is transforming diabetes management, offering greater precision and flexibility in insulin delivery. Companies that can integrate insulin therapies with these advanced technologies have the potential to tap into a growing market segment that values convenience and improved patient outcomes. Furthermore, expanding awareness and health initiatives targeting diabetes prevention and treatment in the Middle East offer opportunities for companies to partner with governments and healthcare providers to promote better disease management and ensure wider insulin access. As demand for personalized care grows, opportunities for new product development, strategic partnerships, and market expansion will continue to emerge, making the Middle East a promising market for human insulin in the coming years.

Market Segmentation Analysis:

By Device:

The Middle East human insulin market is segmented by device type into pens, syringes, and other insulin delivery devices. Insulin pens have emerged as the dominant segment due to their ease of use, portability, and accuracy. Pens offer a more convenient alternative to syringes, with better dosage accuracy and reduced risk of errors. They are particularly popular among Type 1 and Type 2 diabetes patients, as they provide a discreet, user-friendly method of insulin administration. The syringes segment remains relevant, particularly in areas where insulin pens are less accessible or more expensive. However, syringes are gradually being phased out in favor of more advanced delivery systems. The “others” category includes insulin pumps and continuous glucose monitoring systems, which are gaining traction, especially among patients with Type 1 diabetes requiring more precise and continuous insulin management. The increasing adoption of these advanced devices is expected to drive growth in this segment, providing opportunities for new technological advancements and innovations.

By Indication:

The Middle East human insulin market is also segmented by indication, which includes Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Type 1 diabetes dominates the market, as it requires lifelong insulin therapy and typically manifests in younger populations. This segment is particularly prominent in countries like Saudi Arabia and the UAE, where advancements in healthcare allow for better diagnosis and treatment. Type 2 diabetes, however, is rapidly increasing due to lifestyle factors such as poor diet and sedentary behavior. This segment drives significant demand for insulin as the condition progresses and requires insulin therapy to manage blood glucose levels. Gestational diabetes, though less common, is a growing concern in the region, particularly as healthcare awareness improves and more women undergo diabetes screening during pregnancy. As the prevalence of both Type 1 and Type 2 diabetes rises in the Middle East, demand for insulin across all three indications is expected to expand, presenting opportunities for market players to introduce tailored insulin solutions.

Segments:

Based on Device:

Pens
Syringes
Others

Based on Indication:

Type 1 Diabetes
Type 2 Diabetes
Gestational Diabetes

Based on Insulin:

Rapid-acting insulin
Short-acting insulin
Intermediate-acting insulin
Others

Based on Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Based on the Geography:

UAE
KSA
Israel
Turkey
Iran
Rest of Middle East

Regional Analysis

UAE

The UAE stands as one of the leading markets in the Middle East for human insulin. The demand for insulin in the UAE is growing, driven by a high rate of diabetes prevalence, especially type 2 diabetes. As of 2023, the UAE’s market share in the regional insulin market is approximately 15%. The country benefits from a well-established healthcare infrastructure, modern facilities, and a robust supply chain, enabling easy access to diabetes medications. Additionally, the high income levels and increasing awareness of diabetes management significantly contribute to the region’s expanding insulin market.

Saudi Arabia

Saudi Arabia holds the largest market share in the Middle East for human insulin, accounting for nearly 40% of the regional market in 2023. The country’s large diabetic population, coupled with a government-focused health initiative aimed at managing non-communicable diseases, further drives insulin consumption. The demand for human insulin is expected to rise steadily as Saudi Arabia continues to invest in healthcare infrastructure and expand access to essential medications. Both public and private healthcare sectors are showing increasing adoption of insulin therapies to combat diabetes.

Israel

Israel is another prominent market within the Middle East, with a market share of approximately 12% in the region. The country boasts a strong healthcare system that emphasizes advanced medical technologies, including insulin delivery devices and innovative insulin therapies. Israel’s high standard of healthcare and its relatively small but highly affluent population leads to high demand for advanced diabetes care solutions, including human insulin. The market is characterized by the presence of well-established multinational pharmaceutical companies that dominate the insulin sector.

Turkey and Iran

Turkey and Iran together contribute significantly to the Middle East insulin market, accounting for around 25% of the regional share in 2023. Turkey’s insulin market is driven by the increasing adoption of healthcare reforms and the rising number of diabetes patients. With a growing healthcare system and a focus on improving access to medications, Turkey continues to expand its market presence. Similarly, Iran is witnessing steady growth in its human insulin market, driven by the large diabetic population and efforts to increase healthcare accessibility. Although economic sanctions affect market dynamics, local manufacturing and government programs have helped maintain a steady supply of insulin, supporting its growth in the region.

Key Player Analysis

Novo Nordisk A/S
MannKind Corporation
Pfizer
Wockhardt
Biocon
Lupin
Tonghua Dongbao Pharmaceutical Co
Eli Lilly and Company

Competitive Analysis

The Middle East human insulin market is highly competitive, with several key players leading the market. Novo Nordisk A/S, Eli Lilly and Company, Biocon, Pfizer, MannKind Corporation, Wockhardt, Lupin, and Tonghua Dongbao Pharmaceutical Co dominate the market with their wide range of insulin products and strong regional presence. Key players focus on offering a diverse range of insulin products, including both branded and biosimilar options, to cater to the increasing demand driven by rising diabetes prevalence in the region. The competition is intensified by the growing acceptance and adoption of advanced insulin delivery devices, such as insulin pens, pumps, and continuous glucose monitoring systems, which improve patient adherence and treatment outcomes. Companies are also emphasizing cost-effective insulin solutions, particularly biosimilars, to address affordability concerns in a price-sensitive market. In addition to product offerings, players are focusing on expanding their regional presence by forming collaborations with local healthcare providers and distributors. With the growing demand for insulin therapies, companies are also investing in marketing and educational initiatives to raise awareness about diabetes management and promote the accessibility of insulin treatments. The competitive landscape is evolving, with innovation in both treatment options and delivery methods playing a critical role in determining market leadership.

Recent Developments

In April 2025, Novo Nordisk announced the discontinuation of Human Mixtard, India’s largest-selling human insulin brand, as part of a global strategy to prioritize newer, patented diabetes and weight loss therapies such as Ozempic and Wegovy. While vial forms of Mixtard, Actrapid, and Insulatard will remain available, pen devices (Penfills and FlexPens) are being phased out, which is expected to disrupt patient access and preference in India.
In April 2025, Pfizer discontinued the development of danuglipron, its once-daily oral GLP-1 receptor agonist for obesity and type 2 diabetes, following a case of drug-induced liver injury and after reviewing clinical and regulatory feedback. This decision halts further clinical development for both obesity and diabetes indications.
In March 2025, Biocon Biologics entered a strategic collaboration with Civica, Inc. to expand access to Insulin Aspart in the United States. Biocon will supply the drug substance, which Civica will formulate and commercialize after completing development and clinical trials.
In December 2024, Lupin acquired the Huminsulin® portfolio in India from Eli Lilly and Company. The range includes Insulin Human (Huminsulin R, NPH, 50/50, and 30/70) and is indicated for type 1 and type 2 diabetes. Lupin had previously marketed these products under a distribution agreement, and the acquisition is aimed at strengthening its diabetes portfolio.
In November 2024, MannKind’s Afrezza® (insulin human) Inhalation Powder received approval from India’s CDSCO. MannKind expects to ship product to its partner Cipla by the end of 2025.
In October 2024, Wockhardt filed for approval of its fast-acting insulin analog, Aspart injection (ASPARAPID™), with the Drugs Controller General of India (DCGI). The product, developed indigenously, will be offered in cartridges, vials, and prefilled disposable pens. This expands Wockhardt’s diabetes biosimilars portfolio and addresses a market with limited competition.

Market Concentration & Characteristics

The Middle East human insulin market exhibits moderate concentration, with a few dominant global players alongside emerging regional companies. Leading multinational pharmaceutical companies hold a significant market share due to their established insulin portfolios, extensive distribution networks, and strong brand recognition. However, the market is becoming increasingly competitive with the rise of biosimilars and generics, which are driving innovation and providing more affordable insulin options. The characteristics of the market are shaped by the high prevalence of diabetes in the region, prompting governments and healthcare providers to prioritize the availability and affordability of insulin therapies. Companies are focusing on advancing insulin delivery technologies, such as pens and pumps, to improve patient compliance and treatment outcomes. Additionally, the increasing demand for cost-effective insulin solutions, coupled with the expansion of healthcare access in both urban and rural areas, is fueling market dynamics. This competitive environment encourages both established players and newcomers to innovate and adapt.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Report Coverage

The research report offers an in-depth analysis based on Device, Indication, Insulin, Distribution Channel and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The Middle East human insulin market is expected to continue growing due to the rising prevalence of diabetes in the region.
Increasing adoption of advanced insulin delivery systems, such as insulin pens and pumps, will drive market expansion.
The demand for biosimilar insulin products is anticipated to rise as they offer cost-effective alternatives to branded insulin.
Governments in the region are likely to implement more health initiatives focused on improving diabetes management and treatment accessibility.
Technological advancements, such as continuous glucose monitoring and integrated insulin delivery systems, will become more widespread.
Market players will focus on developing personalized insulin therapies to cater to the diverse needs of diabetic patients.
The region will see more collaborations between global and regional pharmaceutical companies to enhance market reach.
Rising healthcare investments and improvements in healthcare infrastructure will increase insulin accessibility across both urban and rural areas.
The shift toward preventive care and early diagnosis will drive higher insulin usage as more people are diagnosed and treated earlier.
Increased focus on patient education and awareness about diabetes management will lead to greater demand for insulin therapies.

CHAPTER NO. 1 : INTRODUCTION 24
1.1.1. Report Description 24
Purpose of the Report 24
USP & Key Offerings 24
1.1.2. Key Benefits for Stakeholders 24
1.1.3. Target Audience 25
1.1.4. Report Scope 25
1.1.5. Regional Scope 26
CHAPTER NO. 2 : EXECUTIVE SUMMARY 27
2.1. Human Insulin Market Snapshot 27
2.1.1. Middle East Human Insulin Market, 2018 – 2032 (USD Million) 28
CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 29
3.1. Russia-Ukraine and Israel-Palestine War Impacts 29
CHAPTER NO. 4 : HUMAN INSULIN MARKET – INDUSTRY ANALYSIS 30
4.1. Introduction 30
4.2. Market Drivers 31
4.2.1. Driving Factor 1 Analysis 31
4.2.2. Driving Factor 2 Analysis 32
4.3. Market Restraints 33
4.3.1. Restraining Factor Analysis 33
4.4. Market Opportunities 34
4.4.1. Market Opportunity Analysis 34
4.5. Porter’s Five Forces Analysis 35
4.6. Value Chain Analysis 36
4.7. Buying Criteria 37
CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 38
5.1. Import Analysis by Region 38
5.1.1. Middle East Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 38
5.2. Export Analysis by Region 39
5.2.1. Middle East Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 39
CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 40
6.1. Demand Analysis by Region 40
6.1.1. Middle East Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 40
6.2. Supply Analysis by Region 41
6.2.1. Middle East Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 41
CHAPTER NO. 7 : PRODUCTION ANALYSIS 42
7.1. Production Analysis by Region 42
7.1.1. Middle East Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 42
CHAPTER NO. 8 : PRICE ANALYSIS 43
8.1. Price Analysis by Region 43
8.1.1. Middle East Human Insulin Market Price, By Region, 2018 – 2023 43
8.1.2. Middle East Device Market Price, By Region, 2018 – 2023 43
8.2. Price Analysis by Device 44
8.2.1. Middle East Human Insulin Market Price, By Device, 2018 – 2023 44
8.2.2. Middle East Device Market Price, By Device, 2018 – 2023 44
CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 45
9.1. Key Raw Materials and Suppliers 45
9.2. Key Raw Materials Price Trend 45
CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 46
10.1. Manufacturing Cost Analysis 46
10.2. Manufacturing Process 46
CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 47
11.1. Company Market Share Analysis – 2023 47
11.1.1. Middle East Human Insulin Market: Company Market Share, by Volume, 2023 47
11.1.2. Middle East Human Insulin Market: Company Market Share, by Revenue, 2023 48
11.1.3. Middle East Human Insulin Market: Top 6 Company Market Share, by Revenue, 2023 48
11.1.4. Middle East Human Insulin Market: Top 3 Company Market Share, by Revenue, 2023 49
11.2. Middle East Human Insulin Market Company Volume Market Share, 2023 50
11.3. Middle East Human Insulin Market Company Revenue Market Share, 2023 51
11.4. Company Assessment Metrics, 2023 52
11.4.1. Stars 52
11.4.2. Emerging Leaders 52
11.4.3. Pervasive Players 52
11.4.4. Participants 52
11.5. Start-ups /SMEs Assessment Metrics, 2023 52
11.5.1. Progressive Companies 52
11.5.2. Responsive Companies 52
11.5.3. Dynamic Companies 52
11.5.4. Starting Blocks 52
11.6. Strategic Developments 53
11.6.1. Acquisitions & Mergers 53
New Product Launch 53
Regional Expansion 53
11.7. Key Players Product Matrix 54
CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 55
12.1. PESTEL 55
12.1.1. Political Factors 55
12.1.2. Economic Factors 55
12.1.3. Social Factors 55
12.1.4. Technological Factors 55
12.1.5. Environmental Factors 55
12.1.6. Legal Factors 55
12.2. Adjacent Market Analysis 55
CHAPTER NO. 13 : HUMAN INSULIN MARKET – BY DEVICE SEGMENT ANALYSIS 56
13.1. Human Insulin Market Overview, by Device Segment 56
13.1.1. Human Insulin Market Revenue Share, By Device, 2023 & 2032 57
13.1.2. Human Insulin Market Attractiveness Analysis, By Device 58
13.1.3. Incremental Revenue Growth Opportunity, by Device, 2024 – 2032 58
13.1.4. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 59
13.2. Pens 60
13.2.1. Middle East Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61
13.2.2. Middle East Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61
13.3. Syringes 62
13.3.1. Middle East Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63
13.3.2. Middle East Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63
13.4. Others 64
13.4.1. Middle East Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65
13.4.2. Middle East Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65
13.5. Device 4 66
13.5.1. Middle East Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67
13.5.2. Middle East Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67
13.6. Device 5 68
13.6.1. Middle East Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69
13.6.2. Middle East Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69
CHAPTER NO. 14 : HUMAN INSULIN MARKET – BY INDICATION SEGMENT ANALYSIS 70
14.1. Human Insulin Market Overview, by Indication Segment 70
14.1.1. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 71
14.1.2. Human Insulin Market Attractiveness Analysis, By Indication 72
14.1.3. Incremental Revenue Growth Opportunity, by Indication, 2024 – 2032 72
14.1.4. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 73
14.2. Type 1 Diabetes 74
14.2.1. Middle East Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75
14.2.2. Middle East Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75
14.3. Type 2 Diabetes 76
14.3.1. Middle East Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77
14.3.2. Middle East Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77
14.4. Gestational Diabetes 78
14.4.1. Middle East Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79
14.4.2. Middle East Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79
14.5. Indication 4 80
14.5.1. Middle East Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81
14.5.2. Middle East Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81
14.6. Indication 5 82
14.6.1. Middle East Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83
14.6.2. Middle East Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83
CHAPTER NO. 15 : HUMAN INSULIN MARKET – BY INSULIN SEGMENT ANALYSIS 84
15.1. Human Insulin Market Overview, by Insulin Segment 84
15.1.1. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 85
15.1.2. Human Insulin Market Attractiveness Analysis, By Insulin 86
15.1.3. Incremental Revenue Growth Opportunity, by Insulin, 2024 – 2032 86
15.1.4. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 87
15.2. Rapid-acting insulin 88
15.2.1. Middle East Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89
15.2.2. Middle East Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89
15.3. Short-acting insulin 90
15.3.1. Middle East Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91
15.3.2. Middle East Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91
15.4. Intermediate-acting insulin 92
15.4.1. Middle East Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93
15.4.2. Middle East Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93
15.5. Others 94
15.5.1. Middle East Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95
15.5.2. Middle East Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95
15.6. Insulin 5 96
15.6.1. Middle East Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97
15.6.2. Middle East Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97
CHAPTER NO. 16 : HUMAN INSULIN MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 98
16.1. Human Insulin Market Overview, by Technology Segment 98
16.1.1. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 99
16.1.2. Human Insulin Market Attractiveness Analysis, By Technology 100
16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 100
16.1.4. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 101
16.2. Technology 1 102
16.2.1. Middle East Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103
16.2.2. Middle East Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103
16.3. Technology 2 104
16.3.1. Middle East Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105
16.3.2. Middle East Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105
16.4. Technology 3 106
16.4.1. Middle East Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107
16.4.2. Middle East Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107
16.5. Technology 4 108
16.5.1. Middle East Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109
16.5.2. Middle East Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109
16.6. Technology 5 110
16.6.1. Middle East Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111
16.6.2. Middle East Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111
CHAPTER NO. 17 : HUMAN INSULIN MARKET – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 112
17.1. Human Insulin Market Overview, by Distribution Channel Segment 112
17.1.1. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 113
17.1.2. Human Insulin Market Attractiveness Analysis, By Distribution Channel 114
17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 114
17.1.4. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 115
17.2. Hospital Pharmacies 116
17.2.1. Middle East Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117
17.2.2. Middle East Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117
17.3. Drug Stores and Retail Pharmacies 118
17.3.1. Middle East Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119
17.3.2. Middle East Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119
17.4. Online Providers 120
17.4.1. Middle East Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121
17.4.2. Middle East Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121
17.5. Distribution Channel 4 122
17.5.1. Middle East Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123
17.5.2. Middle East Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123
17.6. Distribution Channel 5 124
17.6.1. Middle East Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125
17.6.2. Middle East Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125
CHAPTER NO. 18 : HUMAN INSULIN MARKET – REGIONAL ANALYSIS 126
18.1. Human Insulin Market Overview, by Regional Segments 126
18.2. Region 127
18.2.1. Middle East Human Insulin Market Revenue Share, By Region, 2023 & 2032 127
18.2.2. Human Insulin Market Attractiveness Analysis, By Region 128
18.2.3. Incremental Revenue Growth Opportunity, by Region, 2024 – 2032 128
18.2.4. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 129
18.2.5. Middle East Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130
18.2.6. Middle East Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130
18.3. Device 131
18.3.1. Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131
18.4. Middle East Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131
18.5. Indication 132
18.5.1. Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132
18.5.2. Middle East Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132
18.6. Insulin 133
18.6.1. Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133
18.6.2. Middle East Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133
18.7. Technology 134
18.7.1. Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134
18.7.2. Middle East Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134
18.8. Distribution Channel 135
18.8.1. Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135
18.8.2. Middle East Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135
CHAPTER NO. 19 : HUMAN INSULIN MARKET – NORTH AMERICA 136
19.1. North America 136
19.1.1. Key Highlights 136
19.1.2. North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137
19.1.3. North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138
19.1.4. North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139
19.1.5. North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140
19.1.6. North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141
19.1.7. North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142
19.2. U.S. 143
19.3. Canada 143
19.4. Mexico 143
CHAPTER NO. 20 : HUMAN INSULIN MARKET – EUROPE 144
20.1. Europe 144
20.1.1. Key Highlights 144
20.1.2. Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145
20.1.3. Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146
20.1.4. Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147
20.1.5. Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148
20.1.6. Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149
20.1.7. Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150
20.2. UK 151
20.3. France 151
20.4. Germany 151
20.5. Italy 151
20.6. Spain 151
20.7. Russia 151
20.8. Belgium 151
20.9. Netherland 151
20.10. Austria 151
20.11. Sweden 151
20.12. Poland 151
20.13. Denmark 151
20.14. Switzerland 151
20.15. Rest of Europe 151
CHAPTER NO. 21 : HUMAN INSULIN MARKET – ASIA PACIFIC 152
21.1. Asia Pacific 152
21.1.1. Key Highlights 152
21.1.2. Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153
21.1.3. Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154
21.1.4. Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155
21.1.5. Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156
21.1.6. Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157
21.1.7. Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158
21.2. China 159
21.3. Japan 159
21.4. South Korea 159
21.5. India 159
21.6. Australia 159
21.7. Thailand 159
21.8. Indonesia 159
21.9. Vietnam 159
21.10. Malaysia 159
21.11. Philippines 159
21.12. Taiwan 159
21.13. Rest of Asia Pacific 159
CHAPTER NO. 22 : HUMAN INSULIN MARKET – LATIN AMERICA 160
22.1. Latin America 160
22.1.1. Key Highlights 160
22.1.2. Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161
22.1.3. Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162
22.1.4. Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163
22.1.5. Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164
22.1.6. Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165
22.1.7. Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166
22.2. Brazil 167
22.3. Argentina 167
22.4. Peru 167
22.5. Chile 167
22.6. Colombia 167
22.7. Rest of Latin America 167
CHAPTER NO. 23 : HUMAN INSULIN MARKET – MIDDLE EAST 168
23.1. Middle East 168
23.1.1. Key Highlights 168
23.1.2. Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169
23.1.3. Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170
23.1.4. Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171
23.1.5. Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172
23.1.6. Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173
23.1.7. Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174
23.2. UAE 175
23.3. KSA 175
23.4. Israel 175
23.5. Turkey 175
23.6. Iran 175
23.7. Rest of Middle East 175
CHAPTER NO. 24 : HUMAN INSULIN MARKET – AFRICA 176
24.1. Africa 176
24.1.1. Key Highlights 176
24.1.2. Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177
24.1.3. Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178
24.1.4. Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179
24.1.5. Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180
24.1.6. Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181
24.1.7. Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182
24.2. Egypt 183
24.3. Nigeria 183
24.4. Algeria 183
24.5. Morocco 183
24.6. Rest of Africa 183
CHAPTER NO. 25 : COMPANY PROFILES 184
25.1. Novo Nordisk A/S 184
25.1.1. Company Overview 184
25.1.2. Product Portfolio 184
25.1.3. Swot Analysis 184
25.1.4. Business Strategy 185
25.1.5. Financial Overview 185
25.1.6. MannKind Corporation 186
25.1.7. Pfizer 186
25.1.8. Wockhardt 186
25.1.9. Biocon 186
25.1.10. Lupin 186
25.1.11. Tonghua Dongbao Pharmaceutical Co 186
25.1.12. Eli Lilly and Company 186
25.1.13. Company 9 186
25.1.14. Company 10 186
25.1.15. Company 11 186
25.1.16. Company 12 186
25.1.17. Company 13 186
25.1.18. Company 14 186
CHAPTER NO. 26 : RESEARCH METHODOLOGY 187
26.1. Research Methodology 187
26.1.1. Phase I – Secondary Research 188
26.1.2. Phase II – Data Modeling 188
Company Share Analysis Model 189
Revenue Based Modeling 189
26.1.3. Phase III – Primary Research 190
26.1.4. Research Limitations 191
Assumptions 191

List of Figures
FIG NO. 1. Middle East Human Insulin Market Revenue, 2018 – 2032 (USD Million) 30
FIG NO. 2. Porter’s Five Forces Analysis for Middle East Human Insulin Market 37
FIG NO. 3. Value Chain Analysis for Middle East Human Insulin Market 38
FIG NO. 4. Middle East Human Insulin Market Import Volume/Revenue, By Region, 2018 – 2023 40
FIG NO. 5. Middle East Human Insulin Market Export Volume/Revenue, By Region, 2018 – 2023 41
FIG NO. 6. Middle East Human Insulin Market Demand Volume/Revenue, By Region, 2018 – 2023 42
FIG NO. 7. Middle East Human Insulin Market Supply Volume/Revenue, By Region, 2018 – 2023 43
FIG NO. 8. Middle East Human Insulin Market Production Volume/Revenue, By Region, 2018 – 2023 44
FIG NO. 9. Middle East Human Insulin Market Price, By Region, 2018 – 2023 45
FIG NO. 10. Middle East Human Insulin Market Price, By Device, 2018 – 2023 46
FIG NO. 11. Raw Materials Price Trend Analysis, 2018 – 2023 47
FIG NO. 12. Manufacturing Cost Analysis 48
FIG NO. 13. Manufacturing Process 48
FIG NO. 14. Company Share Analysis, 2023 49
FIG NO. 15. Company Share Analysis, 2023 50
FIG NO. 16. Company Share Analysis, 2023 50
FIG NO. 17. Company Share Analysis, 2023 51
FIG NO. 18. Human Insulin Market – Company Volume Market Share, 2023 52
FIG NO. 19. Human Insulin Market – Company Revenue Market Share, 2023 53
FIG NO. 20. Human Insulin Market Revenue Share, By Device, 2023 & 2032 59
FIG NO. 21. Market Attractiveness Analysis, By Device 60
FIG NO. 22. Incremental Revenue Growth Opportunity by Device, 2024 – 2032 60
FIG NO. 23. Human Insulin Market Revenue, By Device, 2018, 2023, 2027 & 2032 61
FIG NO. 24. Middle East Human Insulin Market for Pens, Revenue (USD Million) 2018 – 2032 62
FIG NO. 25. Middle East Human Insulin Market for Syringes, Revenue (USD Million) 2018 – 2032 64
FIG NO. 26. Middle East Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 66
FIG NO. 27. Middle East Human Insulin Market for Device 4, Revenue (USD Million) 2018 – 2032 68
FIG NO. 28. Middle East Human Insulin Market for Device 5, Revenue (USD Million) 2018 – 2032 70
FIG NO. 29. Human Insulin Market Revenue Share, By Indication, 2023 & 2032 73
FIG NO. 30. Market Attractiveness Analysis, By Indication 74
FIG NO. 31. Incremental Revenue Growth Opportunity by Indication, 2024 – 2032 74
FIG NO. 32. Human Insulin Market Revenue, By Indication, 2018, 2023, 2027 & 2032 75
FIG NO. 33. Middle East Human Insulin Market for Type 1 Diabetes, Revenue (USD Million) 2018 – 2032 76
FIG NO. 34. Middle East Human Insulin Market for Type 2 Diabetes, Revenue (USD Million) 2018 – 2032 78
FIG NO. 35. Middle East Human Insulin Market for Gestational Diabetes, Revenue (USD Million) 2018 – 2032 80
FIG NO. 36. Middle East Human Insulin Market for Indication 4, Revenue (USD Million) 2018 – 2032 82
FIG NO. 37. Middle East Human Insulin Market for Indication 5, Revenue (USD Million) 2018 – 2032 84
FIG NO. 38. Human Insulin Market Revenue Share, By Insulin, 2023 & 2032 87
FIG NO. 39. Market Attractiveness Analysis, By Insulin 88
FIG NO. 40. Incremental Revenue Growth Opportunity by Insulin, 2024 – 2032 88
FIG NO. 41. Human Insulin Market Revenue, By Insulin, 2018, 2023, 2027 & 2032 89
FIG NO. 42. Middle East Human Insulin Market for Rapid-acting insulin, Revenue (USD Million) 2018 – 2032 90
FIG NO. 43. Middle East Human Insulin Market for Short-acting insulin, Revenue (USD Million) 2018 – 2032 92
FIG NO. 44. Middle East Human Insulin Market for Intermediate-acting insulin, Revenue (USD Million) 2018 – 2032 94
FIG NO. 45. Middle East Human Insulin Market for Others, Revenue (USD Million) 2018 – 2032 96
FIG NO. 46. Middle East Human Insulin Market for Insulin 5, Revenue (USD Million) 2018 – 2032 98
FIG NO. 47. Human Insulin Market Revenue Share, By Technology, 2023 & 2032 101
FIG NO. 48. Market Attractiveness Analysis, By Technology 102
FIG NO. 49. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 102
FIG NO. 50. Human Insulin Market Revenue, By Technology, 2018, 2023, 2027 & 2032 103
FIG NO. 51. Middle East Human Insulin Market for Technology 1, Revenue (USD Million) 2018 – 2032 104
FIG NO. 52. Middle East Human Insulin Market for Technology 2, Revenue (USD Million) 2018 – 2032 106
FIG NO. 53. Middle East Human Insulin Market for Technology 3, Revenue (USD Million) 2018 – 2032 108
FIG NO. 54. Middle East Human Insulin Market for Technology 4, Revenue (USD Million) 2018 – 2032 110
FIG NO. 55. Middle East Human Insulin Market for Technology 5, Revenue (USD Million) 2018 – 2032 112
FIG NO. 56. Human Insulin Market Revenue Share, By Distribution Channel, 2023 & 2032 115
FIG NO. 57. Market Attractiveness Analysis, By Distribution Channel 116
FIG NO. 58. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 116
FIG NO. 59. Human Insulin Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 117
FIG NO. 60. Middle East Human Insulin Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 118
FIG NO. 61. Middle East Human Insulin Market for Drug Stores and Retail Pharmacies, Revenue (USD Million) 2018 – 2032 120
FIG NO. 62. Middle East Human Insulin Market for Online Providers, Revenue (USD Million) 2018 – 2032 122
FIG NO. 63. Middle East Human Insulin Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 124
FIG NO. 64. Middle East Human Insulin Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 126
FIG NO. 65. Middle East Human Insulin Market Revenue Share, By Region, 2023 & 2032 129
FIG NO. 66. Market Attractiveness Analysis, By Region 130
FIG NO. 67. Incremental Revenue Growth Opportunity by Region, 2024 – 2032 130
FIG NO. 68. Human Insulin Market Revenue, By Region, 2018, 2023, 2027 & 2032 131
FIG NO. 69. North America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 138
FIG NO. 70. Europe Human Insulin Market Revenue, 2018 – 2032 (USD Million) 146
FIG NO. 71. Asia Pacific Human Insulin Market Revenue, 2018 – 2032 (USD Million) 154
FIG NO. 72. Latin America Human Insulin Market Revenue, 2018 – 2032 (USD Million) 162
FIG NO. 73. Middle East Human Insulin Market Revenue, 2018 – 2032 (USD Million) 170
FIG NO. 74. Africa Human Insulin Market Revenue, 2018 – 2032 (USD Million) 178
FIG NO. 75. Research Methodology – Detailed View 189
FIG NO. 76. Research Methodology 190

List of Tables
TABLE NO. 1. : Middle East Human Insulin Market: Snapshot 27
TABLE NO. 2. : Drivers for the Human Insulin Market: Impact Analysis 31
TABLE NO. 3. : Restraints for the Human Insulin Market: Impact Analysis 33
TABLE NO. 4. : Middle East Human Insulin Market Revenue, By Region, 2018 – 2023 43
TABLE NO. 5. : Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 44
TABLE NO. 6. : Key Raw Materials & Suppliers 45
TABLE NO. 7. : Middle East Pens Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 61
TABLE NO. 8. : Middle East Pens Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 61
TABLE NO. 9. : Middle East Syringes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 63
TABLE NO. 10. : Middle East Syringes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 63
TABLE NO. 11. : Middle East Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 65
TABLE NO. 12. : Middle East Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 65
TABLE NO. 13. : Middle East Device 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 67
TABLE NO. 14. : Middle East Device 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 67
TABLE NO. 15. : Middle East Device 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 69
TABLE NO. 16. : Middle East Device 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 69
TABLE NO. 17. : Middle East Type 1 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 75
TABLE NO. 18. : Middle East Type 1 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 75
TABLE NO. 19. : Middle East Type 2 Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 77
TABLE NO. 20. : Middle East Type 2 Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 77
TABLE NO. 21. : Middle East Gestational Diabetes Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 79
TABLE NO. 22. : Middle East Gestational Diabetes Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 79
TABLE NO. 23. : Middle East Indication 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 81
TABLE NO. 24. : Middle East Indication 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 81
TABLE NO. 25. : Middle East Indication 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 83
TABLE NO. 26. : Middle East Indication 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 83
TABLE NO. 27. : Middle East Rapid-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 89
TABLE NO. 28. : Middle East Rapid-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 89
TABLE NO. 29. : Middle East Short-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 91
TABLE NO. 30. : Middle East Short-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 91
TABLE NO. 31. : Middle East Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 93
TABLE NO. 32. : Middle East Intermediate-acting insulin Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 93
TABLE NO. 33. : Middle East Others Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 95
TABLE NO. 34. : Middle East Others Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 95
TABLE NO. 35. : Middle East Insulin 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 97
TABLE NO. 36. : Middle East Insulin 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 97
TABLE NO. 37. : Middle East Technology 1 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 103
TABLE NO. 38. : Middle East Technology 1 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 103
TABLE NO. 39. : Middle East Technology 2 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 105
TABLE NO. 40. : Middle East Technology 2 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 105
TABLE NO. 41. : Middle East Technology 3 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 107
TABLE NO. 42. : Middle East Technology 3 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 107
TABLE NO. 43. : Middle East Technology 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 109
TABLE NO. 44. : Middle East Technology 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 109
TABLE NO. 45. : Middle East Technology 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 111
TABLE NO. 46. : Middle East Technology 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 111
TABLE NO. 47. : Middle East Hospital Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 117
TABLE NO. 48. : Middle East Hospital Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 117
TABLE NO. 49. : Middle East Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 119
TABLE NO. 50. : Middle East Drug Stores and Retail Pharmacies Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 119
TABLE NO. 51. : Middle East Online Providers Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 121
TABLE NO. 52. : Middle East Online Providers Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 121
TABLE NO. 53. : Middle East Distribution Channel 4 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 123
TABLE NO. 54. : Middle East Distribution Channel 4 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 123
TABLE NO. 55. : Middle East Distribution Channel 5 Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 125
TABLE NO. 56. : Middle East Distribution Channel 5 Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 125
TABLE NO. 57. : Middle East Human Insulin Market Revenue, By Region, 2018 – 2023 (USD Million) 130
TABLE NO. 58. : Middle East Human Insulin Market Revenue, By Region, 2024 – 2032 (USD Million) 130
TABLE NO. 59. : Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 131
TABLE NO. 60. : Middle East Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 131
TABLE NO. 61. : Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 132
TABLE NO. 62. : Middle East Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 132
TABLE NO. 63. : Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 133
TABLE NO. 64. : Middle East Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 133
TABLE NO. 65. : Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 134
TABLE NO. 66. : Middle East Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 134
TABLE NO. 67. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 135
TABLE NO. 68. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 135
TABLE NO. 69. : North America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 137
TABLE NO. 70. : North America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 137
TABLE NO. 71. : North America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 138
TABLE NO. 72. : North America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 138
TABLE NO. 73. : North America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 139
TABLE NO. 74. : North America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 139
TABLE NO. 75. : North America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 140
TABLE NO. 76. : North America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 140
TABLE NO. 77. : North America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 141
TABLE NO. 78. : North America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 141
TABLE NO. 79. : North America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 142
TABLE NO. 80. : North America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 142
TABLE NO. 81. : Europe Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 145
TABLE NO. 82. : Europe Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 145
TABLE NO. 83. : Europe Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 146
TABLE NO. 84. : Europe Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 146
TABLE NO. 85. : Europe Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 147
TABLE NO. 86. : Europe Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 147
TABLE NO. 87. : Europe Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 148
TABLE NO. 88. : Europe Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 148
TABLE NO. 89. : Europe Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 149
TABLE NO. 90. : Europe Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 149
TABLE NO. 91. : Europe Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 150
TABLE NO. 92. : Europe Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 150
TABLE NO. 93. : Asia Pacific Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 153
TABLE NO. 94. : Asia Pacific Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 153
TABLE NO. 95. : Asia Pacific Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 154
TABLE NO. 96. : Asia Pacific Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 154
TABLE NO. 97. : Asia Pacific Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 155
TABLE NO. 98. : Asia Pacific Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 155
TABLE NO. 99. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 156
TABLE NO. 100. : Asia Pacific Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 156
TABLE NO. 101. : Asia Pacific Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 157
TABLE NO. 102. : Asia Pacific Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 157
TABLE NO. 103. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 158
TABLE NO. 104. : Asia Pacific Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 158
TABLE NO. 105. : Latin America Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 161
TABLE NO. 106. : Latin America Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 161
TABLE NO. 107. : Latin America Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 162
TABLE NO. 108. : Latin America Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 162
TABLE NO. 109. : Latin America Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 163
TABLE NO. 110. : Latin America Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 163
TABLE NO. 111. : Latin America Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 164
TABLE NO. 112. : Latin America Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 164
TABLE NO. 113. : Latin America Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 165
TABLE NO. 114. : Latin America Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 165
TABLE NO. 115. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 166
TABLE NO. 116. : Latin America Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 166
TABLE NO. 117. : Middle East Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 169
TABLE NO. 118. : Middle East Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 169
TABLE NO. 119. : Middle East Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 170
TABLE NO. 120. : Middle East Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 170
TABLE NO. 121. : Middle East Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 171
TABLE NO. 122. : Middle East Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 171
TABLE NO. 123. : Middle East Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 172
TABLE NO. 124. : Middle East Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 172
TABLE NO. 125. : Middle East Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 173
TABLE NO. 126. : Middle East Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 173
TABLE NO. 127. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 174
TABLE NO. 128. : Middle East Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 174
TABLE NO. 129. : Africa Human Insulin Market Revenue, By Country, 2018 – 2023 (USD Million) 177
TABLE NO. 130. : Africa Human Insulin Market Revenue, By Country, 2024 – 2032 (USD Million) 177
TABLE NO. 131. : Africa Human Insulin Market Revenue, By Device, 2018 – 2023 (USD Million) 178
TABLE NO. 132. : Africa Human Insulin Market Revenue, By Device, 2024 – 2032 (USD Million) 178
TABLE NO. 133. : Africa Human Insulin Market Revenue, By Indication, 2018 – 2023 (USD Million) 179
TABLE NO. 134. : Africa Human Insulin Market Revenue, By Indication, 2024 – 2032 (USD Million) 179
TABLE NO. 135. : Africa Human Insulin Market Revenue, By Insulin, 2018 – 2023 (USD Million) 180
TABLE NO. 136. : Africa Human Insulin Market Revenue, By Insulin, 2024 – 2032 (USD Million) 180
TABLE NO. 137. : Africa Human Insulin Market Revenue, By Technology, 2018 – 2023 (USD Million) 181
TABLE NO. 138. : Africa Human Insulin Market Revenue, By Technology, 2024 – 2032 (USD Million) 181
TABLE NO. 139. : Africa Human Insulin Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 182
TABLE NO. 140. : Africa Human Insulin Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 182

Frequently Asked Questions:

What is the current size of the Middle East Human Insulin?

The market was valued at USD 435.75 million in 2023 and is projected to reach USD 521.17 million by 2032.

What factors are driving the growth of the Middle East Human Insulin?

Rising diabetes prevalence, healthcare reforms, insulin delivery innovations, and biosimilar adoption are driving market growth.

What are the key segments within the Middle East Human Insulin?

Key segments include Device (Pens, Syringes, Others), Indication (Type 1, Type 2, Gestational), Insulin Type, Distribution Channel, and Geography.

What are some challenges faced by the Middle East Human Insulin?

Challenges include high treatment costs, regulatory barriers, and uneven access in rural and underserved regions.

Who are the major players in the Middle East Human Insulin?

Major players include Novo Nordisk, Eli Lilly, Biocon, Pfizer, MannKind, Wockhardt, Lupin, and Tonghua Dongbao.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –